Product: RPL7A Antibody
Catalog: DF9137
Description: Rabbit polyclonal antibody to RPL7A
Application: WB IHC
Cited expt.: WB
Reactivity: Human, Mouse, Rat
Prediction: Zebrafish, Bovine, Sheep, Dog, Chicken, Xenopus
Mol.Wt.: 30kDa; 30kD(Calculated).
Uniprot: P62424
RRID: AB_2842333

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
IHC 1:50-1:200, WB 1:1000-3000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Zebrafish(100%), Bovine(100%), Sheep(100%), Dog(100%), Chicken(100%), Xenopus(92%)
Clonality:
Polyclonal
Specificity:
RPL7A Antibody detects endogenous levels of total RPL7A.
RRID:
AB_2842333
Cite Format: Affinity Biosciences Cat# DF9137, RRID:AB_2842333.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

60S ribosomal protein L7a; L7A; MGC103146; PLA X polypeptide; PLA-X polypeptide; ribosomal protein L7a; RL7A_HUMAN; RP23-414L19.4; RPL7A; SURF 3; SURF-3; SURF3; surfeit 3; Surfeit locus protein 3; Thyroid hormone receptor uncoupling protein; TRUP;

Immunogens

Immunogen:

A synthesized peptide derived from human RPL7A, corresponding to a region within N-terminal amino acids.

Uniprot:
Gene(ID):
Sequence:
MPKGKKAKGKKVAPAPAVVKKQEAKKVVNPLFEKRPKNFGIGQDIQPKRDLTRFVKWPRYIRLQRQRAILYKRLKVPPAINQFTQALDRQTATQLLKLAHKYRPETKQEKKQRLLARAEKKAAGKGDVPTKRPPVLRAGVNTVTTLVENKKAQLVVIAHDVDPIELVVFLPALCRKMGVPYCIIKGKARLGRLVHRKTCTTVAFTQVNSEDKGALAKLVEAIRTNYNDRYDEIRRHWGGNVLGPKSVARIAKLEKAKAKELATKLG

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Bovine
100
Sheep
100
Dog
100
Zebrafish
100
Chicken
100
Xenopus
92
Pig
0
Horse
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Family&Domains:

Belongs to the eukaryotic ribosomal protein eL8 family.

Research Fields

· Genetic Information Processing > Translation > Ribosome.

References

1). SOX1 acts as a tumor hypnotist rendering nasopharyngeal carcinoma cells refractory to chemotherapy. Cell Death Discovery, 2023 (PubMed: 37369660) [IF=7.0]

Application: WB    Species: Human    Sample: NPC cells

Fig. 1 SOX1 decreases ribosome pathway and DNA replication in NPC cells. A An experimental timeline for doxycycline (Blue block: 0 µg/ml, red block: 1 µg/ml) schedules used to control the expression of SOX1 in cells (HONE1 TRE-SOX1 or CNE2 TRE-SOX1). On day 2 and day 4, the cells were counted and proteins were extracted for protein concentration and western blot analysis, respectively. B Western blot analysis of SOX1, RPS3, RPL7A, and β-actin expression in cells. β-actin was used as a control. C Gene set enrichment analysis (GSEA) of ranked genes from cells. Gene set “hsa03010: Ribosome” of KEGG pathways was presented. NES normalized enrichment score. D Scatter dot plots showing the average protein content per cell. E An experimental timeline for doxycycline (Blue block: 0 µg/ml, red block: 1 µg/ml) schedules used to control the expression of SOX1 in cells (HONE1 TRE-SOX1 or CNE2 TRE-SOX1). Both groups of cells were treated with 20 µM BrdU for varying durations, and on day 4, BrdU-positive cells were determined by flow cytometry analysis. F Histograms showing the percentage of BrdU-negative or -positive cells in “SOX1-High” and “SOX1-Low” groups of cells. G Time courses of the percentage of BrdU-positive cells in BrdU incorporation assays, which were fitted by an exponential plateau equation. H An illustration of model hypothesis that overexpression of SOX1 induces quiescent NPC cells. Dox Doxycycline.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.